Codrituzumab

Product Name: Codrituzumab
CAS No.: 1365267-33-9
Chemical Name: Codrituzumab
Synonyms: Codrituzumab;Codrituzumab (anti-GPC3);RG-7686|||RO5137382|||GC33;Research Grade Codrituzumab;Research Grade Codrituzumab(DHE84601);Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE)
CBNumber: CB98080885
Formula Weight: 0
MOL File: Mol file

More

Less

Codrituzumab Property

form: Liquid
color: Colorless to light yellow

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

Codrituzumab Chemical Properties,Usage,Production

Uses

Codrituzumab (GC33) is a humanized monoclonal antibody targeting human GPC3 (glypican-3), with high affinity (Kd of 0.673 nM). GPC3 is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth[1][2][3][4].

References

[1] Mika Endo, et al. Abstract 2747: Anti-glypican-3 monoclonal antibody (codrituzumab/GC33/RO5137382) treatment enhances tumor infiltration of PD-L1-positive macrophages, and combination therapy with anti-PD-L1 monoclonal antibody promotes antitumor effects. Cancer Res (2018) 78 (13_Supplement): 2747.
[2] Chen G, et al. Combining expression of GPC3 in tumors and CD16 on NK cells from peripheral blood to identify patients responding to codrituzumab. Oncotarget. 2018 Jan 2;9(12):10436-10444. DOI:10.18632/oncotarget.23830
[3] Carrasquillo JA, et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma. EJNMMI Res. 2018 Mar 5;8(1):20. DOI:10.1186/s13550-018-0374-8
[4] Abou-Alfa GK, et al. Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol. 2016 Aug;65(2):289-95. DOI:10.1016/j.jhep.2016.04.004

Codrituzumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Codrituzumab Suppliers

China 23 United States 2 Global 25

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

TargetMol Chemicals Inc.

Tel: +1-781-999-5354; +17819995354
Email: marketing@targetmol.com
Country: United States
ProdList: 32435
Advantage: 58

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6762
Advantage: 58

Nantong QuanYi Biotechnology Co., Ltd

Tel: 0513-66337626 18051384581
Email: sales@chemhifuture.com
Country: China
ProdList: 5929
Advantage: 58

Shanghai Yifei Biotechnology Co. , Ltd.

Tel: 021-65675885 18964387627
Email: customer_service@efebio.com
Country: China
ProdList: 11973
Advantage: 58

1365267-33-9, CodrituzumabRelated Search:

Trastuzumab Abciximab Nimotuzumab Matuzumab Pertuzumab Batoclimab Nipocalimab Rozanolixizumab OMALIZUMAB Aprutumab

Codrituzumab

Research Grade Codrituzumab(DHE84601)

Codrituzumab (anti-GPC3)

RG-7686|||RO5137382|||GC33

Research Grade Codrituzumab

Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE)

1365267-33-9